Home / Business and Economy / AI Drug Firm Metis TechBio Raises $270M in HK IPO

AI Drug Firm Metis TechBio Raises $270M in HK IPO

13 May

Summary

Metis TechBio raised HK$2.1 billion ($270 million) in its IPO.
The company uses AI for drug delivery and formulation.
Trading begins in Hong Kong following the successful offering.

AI Drug Firm Metis TechBio Raises $270M in HK IPO

Metis TechBio, a pioneering biotechnology company that employs artificial intelligence for the development and formulation of drugs, is commencing its journey as a publicly traded entity. The company successfully raised HK$2.1 billion, equivalent to $270 million, through its initial public offering on the Hong Kong Stock Exchange.

This significant financial milestone was achieved with shares priced at HK$10.50 each. The successful offering indicates strong investor confidence in Metis TechBio's innovative approach to drug delivery and formulation, powered by cutting-edge AI technologies. The funds raised are expected to fuel the company's continued research and development efforts in the competitive biotechnology landscape.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.